BTG International Ltd (2009) Structured phospholipids. US2009/0036410 A1.Full text not available from this repository.
A method of treating a patient in need of therapy for a disease in which cyokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, is provided comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterifed with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of .gamma.-linolenoyl, dihomo-.gamma.-linolenoyl acid and arachidonoyl.
|Uncontrolled Keywords:||structured phospholipids, cytokines, multiple sclerosis|
|Subjects:||R Medicine > R Medicine (General)|
|Faculty / Department / Research Groups:||Faculty of Engineering & Science > Department of Life & Sports Sciences|
|Last Modified:||05 Dec 2016 14:17|
Actions (login required)